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ABSTRACT
Ovarian cancer is the most aggressive female reproductive tract tumours. Taxane 
(paclitaxel; TX) is widely used for ovarian cancer treatment. However, ovarian cancers 
often acquire chemoresistance. MicroRNAs (miR) have been reported to mediate many 
tumourschemoresistance. We investigated the role of miR-363 in the chemoresistance 
of the ovarian cancer cell line, KF, and its TX-resistant derivative (KF-TX) cells. QRT-
PCR indicated that miR-363 was upregulated in KF-TX cells, and introduction of miR-
363 into sensitive ovarian cancer cells confers TX-resistance and significantly inhibited 
the expression of the Hippo member, LATS2, as indicated by viability, clonogenic assay 
and expression analysis. Furthermore, we validated the role of LATS2 in TX-response 
by sh-based silencing, which also confers TX-resistance to the ovarian cancer cells. On 
the other hand, specific inhibitor against miR-363 restored the response to TX in the 
UHVLVWDQWFHOOV,QDGGLWLRQPL5ZDVIRXQGWRELQGWRWKHĻ875RI/$76P51$
confirming that miR-363 directly targets LATS2 as indicated by dual luciferase assay. 
RT-PCR-based evaluation of miR-363 in a panel of human ovarian tumours revealed 
its upregulation in most of the tumour tissues identified as resistant while it was 
downregulated in most of the tissues identified as sensitive ones. Moreover, higher 
levels of miR-363 in human ovarian cancer specimens were significantly correlated 
with TX chemoresistance. Taken together, our study reveals the involvement of miR-
363 in chemoresistance by targeting LATS2 in ovarian cancers, raising the possibility 
that combination therapy with a miR-363 inhibitor and TX may increase TX efficacy 
and reduce the chance of TX-resistance.
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INTRODUCTION
Epithelial ovarian cancer is the most frequent cause 
of gynaecologic malignancy-related mortality in women 
[1, 2] because 75% of ovarian cancers are detected as 
late-stage disease [3]. Optimal surgical debulking of the 
tumour (no residual disease) followed by chemotherapy 
is the standard regimen for advanced cases [4]. However, 
resistance to combined chemotherapy, platinums coupled 
with taxane (TX) limits the successful treatment [5]. 
Even after achieving clinical remission, unfortunately, 
most patients with advanced epithelial ovarian cancer 
will ultimately develop recurrent disease [6]. Although 
mechanisms of chemoresistance have been widely studied 
in ovarian cancers, many regulators, yet to be discovered.
MicroRNAs (miRNAs or miRs) are, evolutionarily 
conserved, class of 22-nucleotide non-coding RNAs. 
They negatively regulate the coding gene expression in 
a sequence-specific manner [7]. MiRNAs expression 
have been reported in a variety of human cancers 
versus normal, including ovarian cancer [8, 9, 10, 11]. 
Some miRNAs were suggested to have diagnostic and/
or prognostic potencies while some others constitute 
novel targets for cancer treatment [12]. MiRNAs have 
also emerged as important biomolecules regulating 
chemoresponse [13, 14]. Indeed, miRNAs regulate cellular 
apoptosis, expression of multiple drug resistance (MDR)-
related proteins and induction of cancer cell conversion 
to tumour stem-like cells (TSCs) in several cancers [15]. 
Although the role of some miRNAs in the acquisition of 
drug resistance in ovarian cancer cells had been reported 
[16, 17] the role of many miRNAs is still elusive.
Human large tumour suppressor 2 (LATS2, also 
known as KPM), is a member of the LATS tumour 
suppressor family [18], and encodes a putative Ser/Thr 
protein kinase. The kinase activity of LATS2 has been 
implicated in negative regulation of Cyclin E/CDK2 
in tumour suppression [19]. This family acts through 
multiple mechanisms and signalling pathways, including 
those of p53, Hippo and Wnt [20]. LATS proteins were 
overexpressed in nasopharyngeal carcinoma [21], and 
were downregulated in breast carcinoma [22] and non-
small cell lung cancer [23]. Similarly, the expression levels 
of LATS1/2 are altered in a histological type- and disease 
progression-dependent manner in ovarian tumours [24].
LATS2 is involved in cellular proliferation, 
angiogenesis, apoptosis, migration, and invasion [25, 
26]. Moreover, it represents a core component in 
the kinase cascade of the mammalian Hippo growth 
inhibitory pathway [27]. Its dysregulation contributes 
to tumorigenesis. Recently, its deregulation was found 
to occur frequently in a broad range of human cancers, 
including lung [28], liver [29], colon [30] and prostate 
cancers [31], and could correlates with a poor patient 
prognosis.
Here, we report that miR-363 was upregulated in 
TX-resistant ovarian cancer cells. miR-363 was found 
to directly target LATS2. Given that the survival rate of 
patients with high expression of miR-363 was shorter 
than those with low expression profile. MiR-363, together 
with LATS2, might be a potential diagnostic marker to 
predict patient prognosis and responsiveness to TX in 
ovarian cancer while targeting miR-363 may overcome 
TX resistance.
RESULTS
MiR-363 is upregulated in TX-resistant ovarian 
cancer cells
We first established the TX-resistant cells (KF-TX) 
from the parental KF cells (See materials and methods; 
Supplementary Figure 1). Two-day treatment of KF and 
KF-TX cells with 100nM TX displayed very different 
morphology (Figure 1A). Most KF cells were rounded up 
and detached from dishes, whereas KF-TX cells remained 
adherent. Accordingly, induction of sub-G1 fraction, 
which is representing cells undergoing apoptosis, was 
suppressed in KF-TX cells after TX treatment (Figure 
1B). Next, comparative microRNA microarray analysis 
was performed, in which, we found that miR-363 is 
significantly increased in the cells that acquired TX-
resistance. The overexpression of miR-363 was also 
confirmed in KF-TX cells by qRT-PCR (Figure 1C).
MiR-363 confers TX resistance in KF cells
To evaluate the relationship between miR-363 
upregulation and chemoresistance, we established 
stable clones overexpressing miR-363. Flow cytometry 
confirmed the efficiency and expression as indicated by 
GFP expression (Supplementary Figure 2). The qRT-PCR 
also confirmed miR-363 overexpression in the three stable 
clones compared with two control clones (Figure 2A).
To study the impact of miR-363 on the response 
to TX, each stable clone was challenged with different 
concentrations of TX. Cell morphology, after TX-
treatment, clearly indicated that miR-363 overexpressing 
cells were more tolerant to the drug (Figure 2B). Viability 
of miR-363 expressing cells in the presence of 100 
nM of TX for three days was significantly increased in 
comparison to control clones (Figure 2C). Moreover, 
the colonogenic ability in the presence of TX had been 
significantly enhanced in miR-363-expressing cells 
(Figure 2D). Furthermore, transfection of miR-363 
inhibitor had significantly restored the response to TX in 
the KF-TX cells in viability (Figure 2E) and clonogenic 
assays (Figure 2F). These data together demonstrated that 
miR-363 may positively correlate with late TX response. 
To validate our observation, the clonogenic experiment 
Oncotarget30055www.oncotarget.com
was repeated after miR-363 overexpression in another two 
ovarian cancer cell lines, SKOV-3 and OVTOKO cells. 
Importantly, our results concluded the same effect as miR-
363 enhanced the colony forming ability under TX stress 
in both cell lines (Supplementary Figure 3).
MiR-363 downregulates LATS2
To find out the target(s) for miR-363, bioinformatics 
screening using the TargetScan database was performed. 
From the putative targets, we focused our study on those 
with tumour suppression function or those with drug 
Figure 1: miR-363 is upreguated in the TX-resistant versus responsive ovarian cancer cells. (A) Phase contrast images of 
KF cells and KF-TX cells before and after treatment with 100nM of TX. (B) KF cells and KF-TX cells were treated with 100nM TX for 
two days, and subjected to cell cycle analysis by FlowCytometry analysis. (C) RT-PCR results show the upregualtion of miR-363 in the 
TX-resistant cells compared with the parental one.
Oncotarget30056www.oncotarget.com
metabolism-related functions, including RE1-silencing 
transcription factor (REST), sperm Associated Antigen 6 
(SPAG6), phosphatase and tensin homolog deleted from 
chromosome 10 (PTEN), frizzled-1 (FZD1) and large 
tumor suppressor 2 (LATS2). When their expression 
levels were evaluated by western blotting analysis, the 
expression levels of REST, SPAG6, PTEN and FZD1 
were not reduced in miR-363-expressing cells compared 
with their scramble (Supplementary Figure 4). In contrast, 
expression of LATS2 was downregulated in all miR-363-
expressing clones compared with the control transfectants 
(Figure 3A). In addition, endogenous LATS2 was found 
to be downregulated in KF-TX cells compared with the 
parental KF cells (Figure 3B), suggesting that LATS2 is a 
putative target for miR-363 in the cellular set of ovarian 
cancer used here. Moreover, introduction of amiR-363-
specific inhibitor into resistant KF-TX cells significantly 
increased the expression level of LATS2 (Figure 3C).
To confirm that LATS2 is a direct target for miR-
363 in KF cells, we performed luciferase reporter assay. 
)RUWKLVSXUSRVHZHSUHSDUHGZLOGW\SH/$76ƍ875
:7DQGPXWDQW/$76ƍ8750XWZLWKQXFOHRWLGH
substitution in the putative binding site, and subcloned 
them into luciferase reporter vectors giving (luc-WT 
Figure 2: Establishment of miR-363 overexpressing stable clones of KF cells. (A) Two individual control (Ctrl) clones, #1 and 
#2, and the established stable clones, miR-363 1#, 2# and 3#, were subjected to quantitative RT-PCR analysis. The amount of miR-363 was 
normalised by that of gapdh, and data are shown as mean ±standard error (SE) obtained from three independent experiments. (B) Phase 
contrast images of one control (Ctrl) and one representative mir-363-expressing clone (miR-363 1#), after treatment with different doses 
of TX. (C) Control (Ctrl) or miR-363-expressing cells were treated with TX for indicated times and then subjected to cell viability assay 
at the indicated time points. The percentages of the viable cells were plotted as mean ± SE obtained from three independent experiments. 
(D) Two representative clones, control (Ctrl) and miR-363-expressing cells, were subjected to colony formation assay in the presence of 
indicated doses of TX (upper panel) and the survival fractions from three different experiments were calculated (lower panel). KF-TX cells 
were transfected with anti-miR-363 or control oligo then either treated with TX (200nM) for three days followed by cell viability assay (E) 
or subjected to colony forming assay after TX treatment (5nM-40nM) for twelve days The numbers of colonies at each dose were counted 
and normalised to that of untreated cells. The data are shown as mean ± SE obtained from three independent experiments (F).
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and luc-Mut, respectively, Figure 3D). In KF cells, 
overexpressing miR-363, the activity of luc-WT was 
significantly suppressed as compared to control cells, 
whereas no significant differences were observed in the 
luc-Mut activity (Figure 3E). These results suggest that 
miR-363 directly binds to LATS2 mRNA and thus reduces 
the LATS2 protein expression.
miR-363 induces chemoresistance through 
LATS2 targeting
To study whether LATS2 is the major player in miR-
363-induced chemoresistance to TX or not, expression of 
LATS2 was knocked down by shRNA-based siliencing 
in KF cells. Two representative stable clones expressing 
shRNA against LATS2 were established, in which LATS2 
expression was clearly suppressed (confirmed by western 
analysis; Figure 4A). To link this LATS2 inhibition to 
chemoresistance, we performed colonogenic assay in the 
presence of TX and found that, the colony forming ability 
was significantly enhanced in LATS2-knockdown cells 
(Figure 4B and 4C). These results indicate that LATS2 
mediates the response to TX in ovarian cancer cells and 
also indicate that miR-363 may confers TX resistance in 
ovarian cancer cells through downregulation of LATS2.
Nuclear YAP staining negatively correlates with 
miR-363
Yes-associated protein (YAP) is a transcriptional 
co-activator of the Hippo signaling pathway which 
regulates the expression of cellular genes important for 
cell proliferation, cell death, cell migration and epithelial-
mesenchymal transition [28, 30]. In addition, the nuclear 
accumulation of YAP depends on LATS2 level and status 
[14]. Therefore, we decided to study the mechanistic 
consequences of miR-363 overexpression on the YAP 
localization. Immunofluorescence staining revealed 
that miR-363 overexpression significantly reduced the 
number of cells with nuclear YAP (Figure 5A and 5B). 
Although western blotting analysis showed that the 
cells overexpressing miR-363 express relatively higher 
CCND1, a known downstream molecule for the non-
phosphorylated YAP, compared with the empty vector 
transfectant, these cells showed higher expression of the 
anti-apoptotic protein, Bcl2, a well known protecting 
molecule from mitochondrial-dependent apoptosis by TX 
(Figure 5C). Notably, the miR-363 overexpressing clone 
showed slower growth rate compared with the control one 
(Figure 5D). This may explain why killing such cells by 
TX is postponed, probably due to the slow cycling rate. 
Figure 3: LATS2 is downregulated in KF-TX cells and acts as a target for miR-363. Western blotting analysis of LATS2 in 
different stable clones expressing miR-363 and control clones (A), in the parental, KF, cells compared with the resistant, KF-TX cells (B) 
and in the KF cells transfected with scramble or anti-miR-363 oligonucleotides. (C) Actin was used for loading control. (D) Schematic 
GLDJUDP IRU WKH VHTXHQFHRI/$76ƍ875ZLWK WKHPL5ELQGLQJ VLWH DQG IRUGHVLJQRI UHSRUWHU FRQVWUXFW0XWDWLRQ LQWURGXFHG
to inhibit the binding of miR-363. (E) Control or miR-363 expressing, KF, cells were transfected with the luciferase reporter plasmids 
KDUERXULQJHLWKHU/$76ƍ875RULWVPXWDQW$IWHUKWKHFHOOVZHUHWKHQVXEMHFWHGWROXFLIHUDVHDVVD\)LUHIO\OXFLIHUDVHDFWLYLW\ZDV
normalised by Renilla luciferase activity and then shown as relative activity against a control. Data are shown as mean ± SE obtained from 
three independent experiments. *P < 0.05.
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Together, such correlation between miR-363 and YAP1 
translocation may confirm the mechanistic involvement 
of LATS2, as a tumour suppressor in TX-response.
Relationship between miR-363 expression and 
survival of the patients
To evaluate the possible relationship between the 
miR-363-LATS2 axis and development of ovarian cancer 
chemoresistance, we examined the expression level of 
LATS2 in surgical specimens from 10 human ovarian 
cancer tissues (Table 1). All cases were women with FIGO 
stage, IIIc or IV tumours according to FIGO staging and 
underwent complete resection surgery. Histologically, 9 
cases were serous adenocarcinomas, whereas one case was 
endometrioid cancer. The subjects were stratified into two 
groups (sensitive and resistant) by response to subsequent 
taxane-containing chemotherapy within the first year of 
treatment according to the Response Evaluation Criteria 
In Solid Tumors (RECIST) [32]. The regimen contains 
Figure 4: Downregulation of LATS2 induces TX resistance. (A) KF cells were infected with lentiviruses harbouring shLATIS2 or 
control shRNA and stable clones were established by puromycin selection. The cells were then subjected to western blot analysis. Actin was 
used as a loading control. Control cells and LATS2 knockdown cells were subjected to colony formation assay in the presence of indicated 
doses of TX. Representative images are shown (B) The numbers of colonies at each dose were counted and normalised to that of untreated 
cells. The data are shown as mean ± SE obtained from three independent experiments (C).
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combination of paclitaxel (175mg/m2) and carboplatin 
$8&7KHWXPRXUVDPSOHVZHUHGLYLGHGLQWRWZR
groups based on the response to chemotherapy. The 
patients samples were also classified into two groups: 
high and low expression of miR-363, according to 
miR363 expression in the tumour samples as quantified 
by qRT-PCR. We found that the expression of miR363was 
significantly increased in the resistant/high-risk patients 
(Table 1). Survival rate showed that patients with low 
miR-363 expression displayed better prognosis (Figure 
6A). These results suggest that miR-363 expression level 
is related to the chemoresistance and aggressiveness of 
ovarian cancer cells.
In the same research line, we performed 
immunohistochemistry to determine LATS2 expression 
level in the same 10 tissue samples (summarized; 
Table 1). Half of the tissue samples with high LATS2 
expression (represented in Figure 6B.a) were located 
in the chemoresponsive category compared with the 
weak LATS2 expression (represented in Figure 6B.b) 
in most of the tissues categorized as chemoresistant. On 
the other hands, almost half of the tissue samples with 
low expression of miR-363 showed good expression of 
LATS2, however more than half of these tissue samples 
with higher expression of LATS2 showed limited 
expression of mir-363.
DISCUSSION
Currently, the rapid advances in oligonucleotide/
nanoparticle-based therapy create realistic optimism for 
the establishment of miRNAs and/or their inhibitors as a 
potent therapeutic target to control chemoresistance. Many 
of these advanced had applied together with conventional 
therapies including chemotherapy and radiotherapy to 
improve the treatment outcome.
Carboplatin/TX regimen remains the first line and 
the standard treatment course for patients with advanced 
ovarian cancer. Chemoresistance causes the treatment 
failure and recurrence which is still big obstacle in ovarian 
cancer management [5]. The poor prognosis of the ovarian 
cancer patients comes due to late diagnosis and/or poor 
chemoresponse, thus, there is a pressing need to fully 
understand the molecular mechanism(s) responsible for 
Figure 5: miR-363 induces activation of Hippo pathway. (A and B) Control and miR-363-overexpressing, KF, cells were subjected 
to immunofluorescence to analyse localization of YAP1. Representative images are shown (A) The number of cells, in which YAP1 was 
localized in the nuclei, were counted in five different fields, and plotted as a percentage against total counted cells. The data are shown as 
mean ± SE obtained from three independent experiments. (C) Control and miR-363-overexpressing cells were subjected to western blot 
analysis to evaluate the expression levels of CCND1 and Bcl2. (D) Control and miR-363-overexpressing cells were subjected to regular 
culture to get the doubling time. The number of cells at indicated times were counted and plotted. The data were obtained from three 
independent experiments and are shown as mean ± SE.
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chemoresistance. In this study, we proved through of 
evidences that miR-363 decrease and subsequent increase 
of LATS2 are associated with the acquisition of TX-
resistance in ovarian cancer.
MiR-363 is part of the oncogenic miR-1792 
family of clusters. It has been proven to be dysregulated 
in cancers and is profoundly involved in epithelial-
mesenchymal transition, and chemoresistance [3335]. 
Many studies focused on the function of miR-363 which 
showed its role as a tumor suppressor [36] while others 
proved its role as oncogene [37, 38]. Although some 
studies focused on the role of miR-363 in ovarian cancer 
Figure 6: Relationship between patient prognosis and miR-expression. (A) Prognosis of patients with ovarian cancers (four 
FIGO stage IIIc and six FIGO stage IV) were classified into miR363-high (square) and miR363-low (circle) groups. KaplanMeier curves 
were drawn to depict overall survival. *P < 0.05, by log-rank test. Median follow-up ¼ 67 months. (B) LATS2 expression decreased with 
chemoresistance to TX in human ovarian cancers. Representative results of IHC with high expression (+++; a) or low expression (-/+; b) of 
LATS2 are shown as photographs. (C) Schematic diagram for the results of this study. The Hippo pathway was controlled by miR-363 in 
ovarian tumour under stress of TX leading to the acquisition of resistance to TX. Bcl2 was directly or indirectly upregulated when LATS2 
was depleted by miR-363.
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[36], yet, no reports about its role in the chemoresponse 
mechanism/s. We showed, here, for the first time that 
miR-363 mediates resistance to TX. Although we found 
that miR-363 induces slow cellular growth rate in ovarian 
cancer cells, this growth inhibition might be responsible, 
at least in part, for the poor response to TX,. This is, 
probably, because TX, as a microtubules damaging agent, 
kill cancer cells by trapping, then accumulating them in 
the G2/M phase due to tubulin polymerization. In addition, 
our data showed that, like siRNA-based depletion, miR-
363 overexpression reduces LATS2 expression which in 
turn reduce the cellular growth rate, and subsequently 
reduced response to TX in ovarian cancer cells.
Our results showed that TX stress and/or 
chemoresistance conditions are not only associated with 
miR-363 upregulation but also are associated with LATS2 
depletion. Reduction of LATS2, as a tumour suppressor, in 
various cancers, including breast cancer, lung cancer and 
liver cancer was reported [20], which is consistent with our 
finding. Recent studies have shown that silencing of LATS2 
expression promotes cellular invasion in breast cancer, 
while ectopic expression of LATS2 decreases cell invasion 
[20]. LATS2 also acts as a negative regulator of cell growth 
by controlling G1/S and/or G2/M transition [19, 26, 27]. 
For example, in breast cancer, LATS2 mRNA expression 
was downregulated by promoter hypermethylation and 
this alteration was associated with large tumour size, high 
rate of metastasis and estrogen receptor and progesterone 
receptor negativity [39]. Our results support the idea that 
LATS2 expression could be reduced by an alternative 
mechanism, rather than promoter hypermethylation, which 
is the upregulation of miR-363, leading to the acquisition of 
TX resistance in ovarian cancer cells.
LATS2 is mapped to chromosome 13q11-12 
and was reported to be positively expressed in serous 
cystadenomas, with the expression levels gradually 
decreased in borderline cystadenomas and carcinomas 
of the ovary [24]. As a kinase, it also functions as part 
of the Hippo pathway to promote contact inhibition of 
growth and tumor suppression by phosphorylating and 
inhibiting the transcriptional coactivator YAP [25], which 
is confirmed in our cellular set expressing exogenous 
miR-363. However, LATS2 may undermine the ability of 
retinoblastoma protein to induce a permanent cell cycle 
arrest in tumor cells [40].
Importantly, independent of its effects upon YAP or 
tafazzin, LATS2 was reported to have tumor-promoting 
activity not only via modulation of mutant p53 but also 
as a positive regulator of Snail1-mediated epithelial-
mesenchymal transition and survival [41]. Moreover, Li 
et al., (2003) had reported that LATS2 can down-regulate 
antiapoptotic proteins B-cell lymphoma extralarge and 
Bcl-2 to induce apoptosis and inhibit G1/S transition [19]. 
This is consistent with our results which reflect that Bcl-2 
expression was increased in the cells overexpressing miR-
363, probably due to regression of LATS2 expression. 
Based on the fact that Bcl-2 is an important anti-apoptotic 
protein protects ovarian cancer cells from TX and develop 
chemoresisitance. Interestingly, its upregulation after miR-
363 overexpression, probably via LATS2 downregulation, 
may interpret the conferred resistance to TX in our cellular 
set undertaken in this study.
Give that poor survival of ovarian cancer is 
associated with chemoresistence, together with our 
findings, we can speculate that chemoresistance 
established by downregulation of LATS2 may explain 
the relation of miR-363upregulation with poor survival 
of ovarian cancer, albeit in part. Alternatively, it may be 
also possible that downregulation of miR-363 promotes 
metastatic potential of ovarian cancer cells, which might 
Table 1: Relationship between patient clinical course and miR-363 expression in ovarian cancer tissues
Case no. Age FIGO 
stage
10y-OS status (0:live, 
1:dead)
Histology/high grade 
(HG) or low grade (LG)
Chemorespo-
nse status
LATS2 
expression
miR-363/
RNU44
1 48 4 120 0 e Resistant +++ 0.7
2 66 3c 120 0 s/HG Sensitive -/+ 0.7
3 52 4 82 1 s/HG Sensitive -- 0.9
4 51 4 120 0 s/HG Resistant -- 1
5 72 4 21 1 s/HG Resistant ++ 1.14
6 52 3c 105 1 s/HG Resistant -/+ 1.3
7 49 4 46 1 s/HG Resistant -/+ 1.4
8 54 3c 20 1 s/HG Resistant ++ 1.4
9 47 3c 120 0 s/HG Sensitive + 1.4
10 66 4 24 1 s/HG Sensitive ++ 2.29
The table shows the opposite relationship between miR-363 expression and chemoresponse.
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result in poor survival, as previously described in gastric 
cancer cells [38]. Although our immunostaining results 
did not significantly reflect a straightforward relationship 
between LATS2 and miR-363 that could be interpreted 
by the limitation of the tissue samples used here which 
is the main limitation of the current study. However, this 
my open the gate for further work to expand this study 
in a large representing number of ovarian cancer tissues, 
currently running in our lab.
In conclusion, this study describes one of the most 
important biological roles of miR-363 in chemoresponse 
of human ovarian cancer. Our experiments showed 
significant elevation of miR-363 in TX-resistant 
ovarian cancer cells and tissues. MiR-363 promoted the 
chemoresistance of ovarian cancer cells and associated 
with poor survival in clinical samples. In view of 
these results, our study proved that miR-363 directly 
downregulates LATS2 gene expression via binding to its 
ƍ875UHJLRQ0RUHRYHUG\VUHJXODWLRQRIPL5LQD
panel of ovarian cancer tumours supported the idea that 
chemoresistant tumours show high expression of miR-363 
compared with the responsive one.
MATERIALS AND METHODS
Antibodies and reagents
Anti-LATS2, CCND1, REST, SPAG6, PTEN, FZD1 
DQG*$3'+UDEELWSRO\FORQDO$EFDP&DPEULGJH8.
and anti-actin polyclonal (Santa Cruz Biotechnology) 
antibodies were used at 1:1,000 dilution for western 
blotting. Anti-rabbit polyclonal secondary horseradish-
peroxidase-conjugated antibodies (Dako, Glostrup, 
Denmark) was used for detection (diluted; 1:2,000). 
Paclitaxel (TX) was purchased from Sigma (St. Louis, 
MO). The working stock was diluted in the media at a final 
FRQFHQWUDWLRQRIȝ0DQGIXUWKHUGLOXWHGZKHQQHHGHG
Cell lines
The human ovarian serous cancer cell line, SKOV3 
FHOOVZHUHREWDLQHG IURP$7&& 0DQDVVDV9$86$
while the other ovarian serous cancer cell line, KF and 
the clear cell carcinoma cell line, OVTOKO, were kindly 
provided by Prof. Yoshihiro Kikuchi (Department of 
Obstetrics and Gynaecology, National Defence Medical 
College, Saitama, Japan). KF Cells were maintained in 
RPMI-1640 supplemented with 2 mM L-glutamine and 
)&6 6LJPD6W/RXLV0286$.)7;ZHUH
established from parental cell lines KF by maintaining 
them in increasing sublethral concentrations of TX (up 
to10 nM) for more than 10 months. Detection of IC
50
for 
each clone by 3-days viability assay was determined and 
demonstrated that IC
50
 of the KF-TX cells became ten-fold 
higher than the parental cells.
Human ovarian tumours
Tumour specimens from patients with ovarian 
FDQFHU ZHUH REWDLQHG IURP +RNNDLGR 8QLYHUVLW\
Hospital under institutional review board-approval. 
Informed consent was obtained from each patient. 
3DWLHQWV WUHDWHG DW +RNNDLGR 8QLYHUVLW\ +RVSLWDO
between 1999 and 2012 were eligible. Patients were 
treated with taxane/platinum combination regimen. All 
samples were obtained at the initial surgery. MiRNA 
was extracted by Recover-All Total Nucleic Acid 
,VRODWLRQ.LW$PELRQ7;86$IURPIRUPDOLQIL[HG
paraffin-embedded tissues, of which epithelial tumours 
were confirmed by microscopic examination, and miR-
363 was detected by RT-qPCR.
Viability assay
Cell viability was determined by Cell Counting 
Kit (CCK-8; Dojindo, Kumamoto, Japan). Cells from 
different clones were pre-cultured in flat bottom 96-well 
PLFURSODWHVFHOOVZHOOLQDILQDOYROXPHRIȝO
The cells were incubated in a humidified atmosphere 
(37°C, 5% Co
2
)at confluence of 50% for 24h. Seventy-two 
hours after TX treatment, the culture media were replaced 
by the WST-8 reagent 2-(2-methoxy-4-nitrophenyl)-
3-(4-nitrophenyl)-52,4-disulphonyl)-2H-tetrazolium 
monosodium salt) and left in the incubator for 4h. Cellular 
dehydrogenases reduces WST-8 giving orange formazan, 
which is directly proportional to the living cells. The 
absorbance at 450nM was measured by a microplate 
UHDGHU)/82VWDU2PHJD%0*/$%7(&+
Western blotting
Cells were lysed in, NP-40, lysis buffer 
supplemented with Protease Inhibitor Cocktail (Sigma). 
Protein concentration of whole cell lysates was determined 
E\ %UDGIRUG DVVD\ XVLQJ %LRUDG 86$$IWHU ERLOLQJ
with sample buffer, separation by SDD-PAGE, the 
standard western protocol was performed as reported 
elsewhere [44].
RNA extraction and quantitative RT-PCR (qRT-
PCR)
Total RNA was extracted using TRIzol Reagent 
,QYLWURJHQ &DUOVEDG &$ 86$ 7KH PL5 DQG
518 OHYHOV ZHUH TXDQWLILHG XVLQJ T573&5 ZLWK
the TaqMan® MicroRNA Reverse Transcription Kit 
$SSOLHG %LRV\VWHPV )RVWHU &LW\ &$ 86$ DQG
TaqMan® MicroRNA Assays (Applied Biosystems) 
according to the manufacturers instructions. We 
assessed the RNA expression according to Livaket al., 
(2001) [42].
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Overexpression of miR-363
KF cells were transfected with the pCMV-miR-363 
expression vector (Ref. Seq: MI000076425,*(186$
which encodes pre-miR-363. Plasmid DNA transfection 
was done using Effectine (Qiagen, Germany) according 
to the manufacturers instructions. After10-day selection 
E\*ȝJPOWKHVHOHFWHGFORQHVZHUHVFUHHQHG
for miR-363 overexpression using qRT-PCR. Three clones 
were used for further experiments. Similarly, the empty 
vector transfectants were used as a control.
ShRNA interference for LATS2
Two lentivirus strains harbouring short hairpin RNA 
(shRNA) against LATS2 and non-targeting shRNAwere 
SXUFKDVHGIURP*HQH&RSRHLD5RFNYLOOH0'86$.)
cells seeded in one of 48-well plates then infected with the 
lentiviruses at a multiplicity of infection (MOI) at five, 
according to the manufacturers instructions. Two days 
DIWHULQIHFWLRQWHQGD\VVHOHFWLRQE\SXURP\FLQȝJ
ml. media)was performed. Two stable clones were used 
for further experiment after validation of knock down by 
western analysis.
Clonogenic assay
After trypsinization, cells were plated in 6-well 
plates (400cells/well) and incubated for 10 days in the 
regular media with the drug. Colonies were fixed and 
stained with 0.05% crystal violet in 70% methanol for 1h. 
The colonies were counted and images were taken from at 
least three different experiments.
MiR-363 inhibitor
MiRIDIAN microRNA Hairpin Inhibitor and its 
negative control synthetic miRNA inhibitor (MISSION, 
+XPDQ VLJPD$OGULFK 86 ZHUH WUDQVIHFWHG LQWR .)
TX cells(100nM), to transiently inhibit miR-363, using 
Oligofectamine (Invitrogen).
Luciferase reporter assay
Luciferase reporter assay was carried out as 
described elsewhere [43] to test the miR-363/LATS2 
relationship. The firefly luciferase reporter gene expression 
vector, controlled with SV40 enhancer, was purchased 
IURP*HQH&RSRHLD7KHZLOGW\SHRUPXWDQW/$76ƍ
875 VHTXHQFH /$76 10B +PL7
MT06) was inserted downstream of the luciferase gene, 
whereas no oligonucleotides were inserted in the control 
vector. Renilla luciferase was used as a tracking indicator 
for transfection efficiency. The luciferase activity was 
measured using Light Switch Assay Reagent according to 
the manufacturers instructions (Switch Gear Genomics).
Immunofluorescence
Cells were grown on 35-mm glass-based 
dishes (Asahi Glass, Tokyo, Japan), fixed with 3% 
paraformaldehyde and permeabilised with 0.1% Triton 
X-100 in PBS before blocking with 1% bovine serum 
albumin. The cells were incubated with rabbit polyclonal 
antibodies against YAP1 (1:500 dilution, Cell Signaling 
Technology), followed by further incubation withAlexa 
Fluor/594-coupled goat anti-rabbit antibodies (1:250 
dilution, Invitrogen). All samples were examined using 
laser-scanning confocal microscopy (Fluoview, Olympus, 
Tokyo, Japan).
Flow cytometry analysis
Cells were trypsinized and washed twice in 
phosphate-buffered saline (PBS); cell cycle phases were 
then analysed as described [44]. Briefly, cells were 
fixed at 4°C overnight in 70% ethanol. After washing 
ZLWK 3%6 FHOOV ZHUH WUHDWHG ZLWK  ȝJPO 51DVH
7\SH ,$ 6LJPD VWDLQHG ZLWK ȝJPO SURSLGLXP
iodide (PI; Sigma) for 20 min, filtered and kept on ice 
until measurement. The cells were measured by the 
FACSCalibur (BD biosciences) and the data obtained were 
then analysed using ModFit software. Cell fractions with 
a DNA content lower than the G
0
/G
1
 peak, the sub-G0/G1 
fraction, were quantified and considered a marker of the 
percentage of dead/apoptotic cells.
Immunohistochemistry
Ten formalin-fixed, paraffin-embed ovarian 
cancer tumor tissues were used for LATS2 expression 
investigation. Tissues were deparaffinized in xylene and 
rehydrated in descending ethanol series. Antigen retrieval 
was accomplished through microwave irradiation of the 
sections in 10mM sodium citrate buffer. Slides were 
incubated with rabbit anti-LATS2 polyclonal antibody, 
and then incubated with biotin-conjugated goat anti-
rabbit IgG (Jackson Immunoresearch Laboratories, 
:HVW*URYH3$86$7KHERXQGLPPXQHFRPSOH[HV
were developed by addition of diaminobenzidine (DAB; 
6LJPD$OGULFK6W/RXLV0286$DQGWKHQXFOHLZHUH
stained with hematoxylin (Sigma-Aldrich). The sections 
were also incubated with normal goat serum as a negative 
FRQWURO6DPSOHVZHUHYLHZHGXVLQJ1LNRQ7(8
microscope (NIKON, Tokyo, Japan). All of the slides 
were reviewed by three full-boarded pathologists without 
knowledge of the clinical data. Immunohistochemical 
positivity was evaluated by proportion and intensity. For 
analysis of proportion, four tired evaluation was applied 
as 0 to 3: no staining (0), 110% (1), 1150% (2) and 
51100% of tumor cells (3). For evaluation of intensity, 
we used following four criteria: negative (0;-), weak 
(1;+), intermediate (2;++) and strong (3;+++). LATS2 
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immunohistochemistry score was shown as sum of 
proportional and intensity scores (0 to 6).
Statistical analysis
Statistical analysis was performed using Minitab 
Release (Ver.12). Data were subjected to one-way analysis 
of variance, followed by comparison using student t test 
to evaluate the difference between means. Differences 
between means were considered significant if p-values 
<0.05.
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